Nplate Sales: Sales of Nplate® (romiplostim) increased 38 percent to $90 million in the first quarter of 2012 versus $65 million in the first quarter of 2011. These increases were driven primarily by global unit growth. http://www.amgen.com/media/media_pr_detail.jsp?releaseID=1686784